Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Medro vs TeleClinic

Medro
Graded #256

Higher grade

vs+2.8000000000000043
TeleClinic
Graded #314

Lower grade

The verdict

Medro takes it — 63.6/100 to 60.8/100.

Medro grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Medro (Medro Health Technologies, Inc.) is a telehealth brand whose GLP-1 program offers compounded semaglutide and tirzepatide, plus brand-name GLP-1s when eligible, via a partner medical group and…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMedro +6
50
44
Dose & formulationMedro +13
77
64
Clinical oversightTeleClinic +9
71
80
Labs & monitoringEven
52
52
FulfillmentTeleClinic +5
92
97
Contract termsMedro +13
33
20
Medro · left barTeleClinic · right bar

The numbers

MetricMedroTeleClinic
WeighScore63.6/10060.8/100
GradeCC
Scorecard rank#256#314
Semaglutide$199/mo (compounded)$199/mo (compounded)
Tirzepatide$299/mo (compounded)$299/mo (compounded)
CoverageAll 50 states47 states
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
Medro

Graded #256 · C

Strengths

  • Covers both compounded semaglutide and tirzepatide and can prescribe brand-name GLP-1s when clinically appropriate.
  • LegitScript-certified (seal #50716646), available in all 50 states, with tiered pricing shown before checkout.
  • No membership fee and free expedited shipping on all orders; online intake with no appointment required in many cases.
  • Prices drop with longer commitments (semaglutide to $149/mo, tirzepatide to $224/mo on a 12-month plan).

Where it loses points

  • Does not name its compounding pharmacy or its clinical partner medical group, so the fulfillment chain is not verifiable.
  • Pricing is described as illustrative and may change by dose, pharmacy availability, and eligibility — final cost shows only at checkout.
  • Very new brand (2026, trademark pending) spanning many verticals, with a short track record in GLP-1 care.
  • Compounded medications are not FDA-approved or therapeutically equivalent to Ozempic, Wegovy, Mounjaro, or Zepbound.
TeleClinic

Graded #314 · C

Strengths

  • Names its pharmacy partner — Rush Pharmacy, a licensed 503A compounder — which many compounded-GLP-1 telehealths won't disclose
  • LegitScript certified with flat, published monthly pricing, free shipping, and no insurance required
  • Broad access: 47 states with US-licensed physicians and transparent cash-pay pricing

Where it loses points

  • Compounded semaglutide and tirzepatide only — no brand-name GLP-1 (Wegovy or Zepbound) option
  • Headline $139/$219 rates are first-quarter intro prices billed quarterly; ongoing month-to-month is $199/$299
  • Not available in California, South Carolina, or New Jersey

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard